Spots Global Cancer Trial Database for refractory anemia with excess blasts

Every month we try and update this database with for refractory anemia with excess blasts cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies	NCT01175785	Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Myelo...	umbilical cord ... fludarabine pho... cyclophosphamid... ex vivo-expande... total-body irra... cyclosporine mycophenolate m... laboratory biom...	6 Months - 45 Years	Nohla Therapeutics, Inc.
Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome	NCT00003171	Leukemia Myelodysplastic...	bryostatin 1	18 Years -	Barbara Ann Karmanos Cancer Institute
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation	NCT00052520	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... B-cell Adult Ac... B-cell Childhoo... Childhood Chron... Childhood Myelo... Chronic Myelomo... Essential Throm... Polycythemia Ve... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... T-cell Adult Ac... T-cell Childhoo...	therapeutic all... aldesleukin peripheral bloo... allogeneic bone... laboratory biom... gene expression... immunologic tec... flow cytometry polymerase chai... cytogenetic ana... staining method	-	Fred Hutchinson Cancer Center
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome	NCT00003123	Myelodysplastic...	amifostine trih...	17 Years -	National Cancer Institute (NCI)
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA	NCT02562443	Myelodysplastic... MDS Refractory Anem... RAEB	rigosertib Any approved or... best supportive... best supportive...	18 Years - 81 Years	Traws Pharma, Inc.
Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia	NCT00003602	Leukemia Myelodysplastic...	cytarabine etoposide idarubicin mitoxantrone hy...	55 Years -	National Cancer Institute (NCI)
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome	NCT00017550	Myelodysplastic...	anti-thymocyte ...	18 Years - 120 Years	Sanofi
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers	NCT00015951	Leukemia Myelodysplastic...	bevacizumab cytarabine mitoxantrone hy...	18 Years - 120 Years	University of Maryland, Baltimore
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia	NCT00003619	Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni...	filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo...	19 Years - 90 Years	National Cancer Institute (NCI)
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia	NCT00357565	Leukemia Myelodysplastic... Childhood Acute... Recurrent Child... Secondary Acute... Childhood Acute... Previously Trea... Secondary Myelo... Refractory Anem... Refractory Anem... Refractory Anem... De Novo Myelody... Childhood Myelo...	filgrastim busulfan cyclosporine fludarabine pho... melphalan mycophenolate m... umbilical cord ...	- 3 Years	Masonic Cancer Center, University of Minnesota
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases	NCT00376519	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo...	cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra...	18 Years - 45 Years	Masonic Cancer Center, University of Minnesota
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia	NCT00818649	Leukemia Myelodysplastic...	bortezomib vorinostat	18 Years -	Masonic Cancer Center, University of Minnesota
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD	NCT00914940	Graft Versus Ho... Leukemia Myelodysplastic...	Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted...	14 Years - 55 Years	Fred Hutchinson Cancer Center
Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes	NCT00398047	Leukemia Myelodysplastic...	Azacitadine and...	- 120 Years	Wake Forest University Health Sciences
Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome	NCT00004208	Myelodysplastic...	ATG + CSA Supportive care	18 Years -	Swiss Group for Clinical Cancer Research
Gemtuzumab in Treating Patients With Myelodysplastic Syndrome	NCT00022321	Myelodysplastic...	gemtuzumab ozog...	18 Years -	National Cancer Institute (NCI)
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies	NCT00070538	Leukemia Myelodysplastic...	cytarabine laromustine	18 Years -	National Cancer Institute (NCI)
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes	NCT00234000	Leukemia Myelodysplastic...	arsenic trioxid... azacitidine	18 Years -	Jonsson Comprehensive Cancer Center
Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome	NCT00003415	Leukemia Myelodysplastic...	amifostine trih... topotecan hydro...	18 Years -	National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome	NCT00002800	Leukemia Myelodysplastic... Neutropenia	filgrastim lintuzumab cytarabine etoposide idarubicin	18 Years -	Memorial Sloan Kettering Cancer Center
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer	NCT00003661	Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma	anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera...	- 54 Years	Roswell Park Cancer Institute
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia	NCT00006213	Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron...	BMS-214662 pharmacological... laboratory biom...	15 Years -	National Cancer Institute (NCI)
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	NCT02566304	Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom...	18 Years -	Thomas Jefferson University
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes	NCT00352001	Leukemia Myelodysplastic...	azacitidine lenalidomide	18 Years - 120 Years	Case Comprehensive Cancer Center
Chemotherapy in Treating Patients Who Have Hematologic Cancer	NCT00004047	Leukemia Myelodysplastic...	exatecan mesyla...	-	Daiichi Sankyo
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD	NCT00914940	Graft Versus Ho... Leukemia Myelodysplastic...	Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted...	14 Years - 55 Years	Fred Hutchinson Cancer Center
Paricalcitol in Treating Patients With Myelodysplastic Syndrome	NCT00064376	Leukemia Myelodysplastic...	paricalcitol	25 Years - 100 Years	Cedars-Sinai Medical Center
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation	NCT00005641	Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic...	anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera...	15 Years - 60 Years	H. Lee Moffitt Cancer Center and Research Institute
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia	NCT00278330	Blastic Phase C... Recurrent Adult... Recurrent Adult... Refractory Anem... Relapsing Chron... Untreated Adult... Untreated Adult...	alvocidib vorinostat	18 Years -	National Cancer Institute (NCI)
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	NCT00087204	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo...	becatecarin laboratory biom...	18 Years -	National Cancer Institute (NCI)
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes	NCT00997243	Leukemia Myelodysplastic...	lintuzumab 5-azacytidine	18 Years -	Ohio State University Comprehensive Cancer Center
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	NCT00454480	Leukemia Myelodysplastic...	alemtuzumab arsenic trioxid... azacitidine busulfan clofarabine cytarabine daunorubicin hy... fludarabine pho... gemtuzumab ozog... melphalan tipifarnib DNA methylation... cytogenetic ana... gene expression... mutation analys... diagnostic labo... immunologic tec... allogeneic hema... nonmyeloablativ...	-	National Cancer Institute (NCI)
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies	NCT00070538	Leukemia Myelodysplastic...	cytarabine laromustine	18 Years -	National Cancer Institute (NCI)
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA	NCT02562443	Myelodysplastic... MDS Refractory Anem... RAEB	rigosertib Any approved or... best supportive... best supportive...	18 Years - 81 Years	Traws Pharma, Inc.
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	NCT00119366	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Myelo... Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Acute... Secondary Myelo...	iodine I 131 mo... fludarabine pho... total-body irra... allogeneic hema... peripheral bloo... cyclosporine mycophenolate m... laboratory biom...	16 Years - 50 Years	Fred Hutchinson Cancer Center
S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia	NCT00005866	Leukemia Myelodysplastic...	busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... radiation thera...	16 Years - 55 Years	SWOG Cancer Research Network
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer	NCT00296023	Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo...	18 Years - 75 Years	University of California, San Francisco
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia	NCT00002926	Leukemia Myelodysplastic...	cytarabine etoposide idarubicin allogeneic bone... peripheral bloo...	16 Years - 60 Years	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia	NCT00003436	Leukemia Myelodysplastic...	amsacrine asparaginase cytarabine daunorubicin hy... etoposide methotrexate mitoxantrone hy... therapeutic hyd... allogeneic bone...	- 15 Years	National Cancer Institute (NCI)
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer	NCT00290641	Chronic Myelopr... Leukemia Lymphoma Myelodysplastic...	filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera...	- 45 Years	Masonic Cancer Center, University of Minnesota
Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome	NCT00003959	Leukemia Myelodysplastic...	ras peptide can... sargramostim	17 Years -	Memorial Sloan Kettering Cancer Center
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer	NCT00003661	Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma	anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera...	- 54 Years	Roswell Park Cancer Institute
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome	NCT00002547	Leukemia Myelodysplastic...	busulfan cyclophosphamid... cyclosporine cytarabine methotrexate allogeneic bone... syngeneic bone ...	- 60 Years	Barbara Ann Karmanos Cancer Institute
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome	NCT00002798	Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Secondary Myelo... Untreated Child...	asparaginase daunorubicin hy... fludarabine pho... therapeutic hyd... allogeneic bone... 3-dimensional c... filgrastim cytarabine idarubicin dexamethasone thioguanine etoposide methotrexate cyclophosphamid... aldesleukin busulfan	- 21 Years	National Cancer Institute (NCI)
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders	NCT00397813	Atypical Chroni... Chronic Myelomo... de Novo Myelody... Essential Throm... Myeloproliferat... Paroxysmal Noct... Polycythemia Ve... Polycythemia Ve... Primary Myelofi... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Total-Body Irra...	50 Years - 75 Years	Fred Hutchinson Cancer Center
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia	NCT00006213	Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron...	BMS-214662 pharmacological... laboratory biom...	15 Years -	National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Advanced Hematologic Cancer	NCT00005967	Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	tipifarnib	18 Years -	National Cancer Institute (NCI)
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes	NCT00352001	Leukemia Myelodysplastic...	azacitidine lenalidomide	18 Years - 120 Years	Case Comprehensive Cancer Center
Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome	NCT00003984	Myelodysplastic...	lintuzumab	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy	NCT00005942	Chronic Myelomo... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem...	liposomal dauno... semaxanib laboratory biom...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome	NCT00003827	Leukemia Myelodysplastic...	amifostine trih... cytarabine topotecan hydro...	16 Years -	National Cancer Institute (NCI)
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	NCT00087204	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo...	becatecarin laboratory biom...	18 Years -	National Cancer Institute (NCI)
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant	NCT00376480	Leukemia Myelodysplastic...	anti-thymocyte ... peripheral bloo... fludarabine pho... methylprednisol... thiotepa allogeneic hema... in vitro-treate... total-body irra...	- 50 Years	Dana-Farber Cancer Institute
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy	NCT00006220	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	arsenic trioxid... tretinoin	15 Years -	Washington University School of Medicine
Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease	NCT00295971	Congenital Ameg... Leukemia Myelodysplastic... Severe Congenit...	anti-thymocyte ... therapeutic all... fludarabine pho... thiotepa allogeneic bone... allogeneic hema... in vitro-treate... total-body irra...	1 Year - 17 Years	University of California, San Francisco
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer	NCT00534430	Leukemia Myelodysplastic...	busulfan cyclosporine etoposide mycophenolate m... allogeneic bone... allogeneic hema... peripheral bloo... total-body irra...	16 Years - 50 Years	City of Hope Medical Center
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer	NCT00295880	Myeloproliferat... Leukemia Lymphoma Myelodysplastic...	umbilical cord ...	12 Years - 45 Years	Masonic Cancer Center, University of Minnesota
Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia	NCT01146210	Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Fanconi Anemia Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Secondary Myelo... Untreated Child...	laboratory biom...	- 21 Years	Children's Oncology Group
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant	NCT00376480	Leukemia Myelodysplastic...	anti-thymocyte ... peripheral bloo... fludarabine pho... methylprednisol... thiotepa allogeneic hema... in vitro-treate... total-body irra...	- 50 Years	Dana-Farber Cancer Institute
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant	NCT00107354	Leukemia Myelodysplastic...	aldesleukin therapeutic all... therapeutic aut... cytarabine etoposide mitoxantrone hy... allogeneic bone... peripheral bloo...	14 Years -	Fred Hutchinson Cancer Center
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	NCT02566304	Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom...	18 Years -	Thomas Jefferson University
Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	NCT00008177	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Myelo... Untreated Adult...	iodine I 131 mo... total-body irra... allogeneic hema... peripheral bloo... fludarabine pho... cyclosporine mycophenolate m... laboratory biom...	50 Years -	Fred Hutchinson Cancer Center
S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome	NCT00016419	Leukemia Myelodysplastic...	anti-thymocyte ... cyclosporine	15 Years -	SWOG Cancer Research Network
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia	NCT00096122	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Refractory Anem... Refractory Anem... Secondary Acute... Secondary Myelo... Untreated Adult...	cytarabine idarubicin tipifarnib	15 Years - 70 Years	National Cancer Institute (NCI)
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders	NCT00397813	Atypical Chroni... Chronic Myelomo... de Novo Myelody... Essential Throm... Myeloproliferat... Paroxysmal Noct... Polycythemia Ve... Polycythemia Ve... Primary Myelofi... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Total-Body Irra...	50 Years - 75 Years	Fred Hutchinson Cancer Center
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia	NCT00096122	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Refractory Anem... Refractory Anem... Secondary Acute... Secondary Myelo... Untreated Adult...	cytarabine idarubicin tipifarnib	15 Years - 70 Years	National Cancer Institute (NCI)
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS	NCT01607645	Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Previously Trea... Recurrent Adult... Refractory Anem...	decitabine idarubicin cytarabine	18 Years -	Fred Hutchinson Cancer Center
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes	NCT00104962	Childhood Myelo... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Myelo... Unspecified Chi...	lenalidomide	1 Year - 21 Years	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia	NCT00003436	Leukemia Myelodysplastic...	amsacrine asparaginase cytarabine daunorubicin hy... etoposide methotrexate mitoxantrone hy... therapeutic hyd... allogeneic bone...	- 15 Years	National Cancer Institute (NCI)
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm	NCT01101880	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Chronic Myelomo... de Novo Myelody... Refractory Anem... Untreated Adult... Myeloproliferat...	filgrastim clofarabine cytarabine	18 Years - 64 Years	University of Washington
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia	NCT00046930	Leukemia Myelodysplastic...	filgrastim sargramostim cytarabine daunorubicin hy... zosuquidar trih... Placebo	60 Years -	Eastern Cooperative Oncology Group
Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome	NCT00003681	Anemia Myelodysplastic...	epoetin alfa amifostine trih...	18 Years -	National Cancer Institute (NCI)
Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome	NCT00513578	Myelodysplastic...	PR1 leukemia pe... incomplete Freu... sargramostim	18 Years -	National Cancer Institute (NCI)
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes	NCT00098826	Acute Undiffere... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... Untreated Adult...	ispinesib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine	NCT01928537	Myelodysplastic... Refractory Anem... Chronic Myelomo... Cytopenia	rigosertib sodi...	18 Years -	Traws Pharma, Inc.

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: